Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets
This study examines the effect and interaction of variations in hypromellose physicochemical properties.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 106-116

References

1. L.X. Yu, Pharm. Res. 25(4), 781–791 (2008).

2. T.D. Cabelka et al., "Application of Quality by Design Principles to the Formulation of aHydrophilic Matrix Tablet of a High Dose/High Solubility Drug," presented at the AAPS Annual Meeting (Los Angeles, 2009).

3. T.D Cabelka et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Propranolol Hydrochloride Hydrophilic Matrix Tablets," presented at the AAPS Annual Meeting (New Orleans, 2010).

4. H. Deng et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Theophylline Hydrophilic Matrix Tablets," presented at the CRS Annual Meeting and Exposition (National Harbor, Maryland, 2011).

5. A.S. Rathore and H. Winkle, Nature Biotechnol. 27 (1) 26–34 (2009).

6. ICH, ICH Q8(R2) Pharmaceutical Development (2009).

7. USP 30–NF 25, "USP Monographs: Hypromellose," online, http://www.uspnf.com/, accessed May 10, 2008.

8. J.E. Hogan, Drug Dev. Ind. Pharm. 15 (6), 975–1999 (1989).

9. P. Gao et al., J. Pharm. Sci. 85 (7), 732–740 (1996).

10. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci. 93 (11), 2746–2754 (2004).

11. K. Mitchell et al., Int. J. Pharm. 66 (1–3), 233–242 (1990).

12. A.R. Rajabi-Siahboomi, A. Nokhodchi, and M.H. Rubinstein, "Compaction Behavior of Hydrophilic Cellulose Ether Polymers," in Pharm. Technol. Yearbook: Tableting and Granulation (1998), pp. 32–40 .

13. R.W. Korsmeyer et al., Int. J. Pharm. 15 (1), 25–35 (1983).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here